A recent study demonstrated improved T cell durability and efficacy in tumor control after introducing glucose transporter (Glut) overexpression, and, given our findings, a similar potentially profitable target to counter the tumor T cell exhaustion phenotype would be increased SERCA pump expression [30]. This evidence concerns the gene SLC2A1 and neoplasm.